Clinical Trials

Erimos has several clinical studies ongoing or soon to be initiated in 2007, as highlighted below.

Terameprocol is in Phase I clinical studies evaluating its use as an intravenous therapy for refractory and metastatic solid tumors and hematological malignancies unresponsive to conventional therapy. The first intravenous clinical trial in patients with refractory metastatic solid tumors administers terameprocol for 5 consecutive days every 28 days. This study is being conducted at three U.S. sites including Albert Einstein College of Medicine in Bronx, N.Y.; Premiere Oncology of Scottsdale, Ariz.; and a site in Nashville, Tenn. Patient enrollment in this study has been completed. 

A second Phase I study in patients with metastatic solid tumors that are not responding to standard therapies will soon be enrolling patients. This study will administer terameprocol as a continuous 24-hour intravenous infusion on a weekly basis.

Erimos is proud to be partnering with the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium to conduct a Phase I study with intravenous terameprocol in adults with recurrent and refractory glioma. Enrollment in this study is underway at nine Consortium centers of excellence in the US.

Erimos will soon begin a Phase I study of intravenous terameprocol in adults with hematological malignancies (ALL, AML and CLL). This study is scheduled to begin enrollment in the third quarter of 2007.

Terameprocol has also been evaluated in a Phase II clinical pilot study for use as an intravaginal therapy for the treatment of Cervical Intraepithelial Neoplasia (CIN), a viral-induced (human papilloma virus) pre-cancerous change in the cervix. The pilot clinical study demonstrated encouraging results for this indication.

Erimos has additionally completed a Phase I study of intralesional terameprocol in refractory head and neck cancer.

Additional information about these trials can be found at www.clinicaltrials.gov. Please use the search term “EM-1421”, or just click here to go straight to the EM-1421 search results.